Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

KalVista Announces Start of Clinical Development for Novel Treatment for DME

Published: Thursday, August 21, 2014
Last Updated: Thursday, August 21, 2014
Bookmark and Share
Phase I trial of plasma kallikrein inhibitor to be conducted in the US.

KalVista Pharmaceuticals has announced that it has begun a Phase I, First in Human, trial of its novel plasma kallikrein inhibitor, KVD001, for the treatment of DME. The study’s Principal Investigator is Dr. Jennifer K Sun of the Beetham Eye Institute, Joslin Diabetes Center; Harvard Medical School Department of Ophthalmology, Boston, MA and is being conducted under KalVista’s open Investigational New Drug Application (IND) from the United States Food and Drug Administration (FDA). KVD001 has been advanced under a research partnership between KalVista and JDRF.

The study is an open label, single ascending dose study to investigate the safety, tolerability and pharmacodynamics of KVD001 delivered by intravitreal injection (ClinicalTrials.gov identifier NCT02193113). First patients were dosed in August and recruitment is ongoing at five centers in the US.

Dr Jennifer Sun said: “DME is a leading cause of adult visual loss in developed countries and new approaches for DME are a major unmet medical need. KalVista’s novel plasma kallikrein inhibitor could offer a therapeutic approach to the treatment of the condition that targets different molecular pathways than currently available therapies. We look forward to completing the first clinical study with KVD001.”

Andrew Crockett, KalVista CEO, said: “Today’s announcement of the start of clinical development for KVD001 is a significant step for KalVista. Our collaboration with the JDRF has been very productive and we are delighted to begin this study of a new treatment we hope will ultimately improve outcomes for patients with what is a very serious complication in diabetes.”

Plasma kallikrein is a serine protease that represents an attractive drug target in people with diabetic retinopathy as it is has been shown to contribute to blood vessel leakage and thickening of the retina through the collaborative work of Drs. Edward P Feener and Lloyd Paul Aiello at the Joslin Diabetes Center.

The detrimental effects of plasma kallikrein on the retina in patients with diabetes are mediated by mechanisms that are independent of vascular endothelial growth factor (VEGF), which has been an area of intense recent interest as a target for treating DME.

However, while intravitreal VEGF inhibitors have shown clear benefit in clinical trials in many patients through reducing macular edema and increasing visual acuity, a substantial proportion of DME patients do not respond fully to anti-VEGF treatment.

KalVista’s approach, targeting plasma kallikrein inhibition, has the potential to add to the treatment options for sufferers of DME including those that are non-responsive to VEGF inhibitors.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New EU Consortium Focused on Discovery and Development of Novel Eye Therapeutics
Consortium supported by EU Seventh Framework Programme.
Monday, October 14, 2013
KalVista Wins £2.4m Biomedical Catalyst Grant
Grant to further develop oral plasma kallikrein inhibitors as a treatment for diabetic macular edema.
Tuesday, November 06, 2012
Scientific News
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!